688506 百利天恒
已收盘 06-18 15:00:01
资讯
新帖
简况
百利天恒最新公告：EGFR×HER3双抗ADC治疗三阴乳腺癌上市申请获受理
证券之星 · 06-14
百利天恒最新公告：EGFR×HER3双抗ADC治疗三阴乳腺癌上市申请获受理
百利天恒最新公告：注射用BL-M14D1（DLL3ADC）联合用药治疗广泛期小细胞肺癌药物临床试验获批准
证券之星 · 06-14
百利天恒最新公告：注射用BL-M14D1（DLL3ADC）联合用药治疗广泛期小细胞肺癌药物临床试验获批准
百利天恒涨6.24%，开源证券一个月前给出“买入”评级
证券之星 · 06-12
百利天恒涨6.24%，开源证券一个月前给出“买入”评级
百利天恒：60亿元科技创新债券注册获批
财中社 · 06-11
百利天恒：60亿元科技创新债券注册获批
百利天恒获准发行60亿元中期票据
美股速递 · 06-11
百利天恒获准发行60亿元中期票据
6月10日百利天恒涨5.30%，中欧医疗健康混合A基金重仓该股
证券之星 · 06-10
6月10日百利天恒涨5.30%，中欧医疗健康混合A基金重仓该股
山西证券：给予百利天恒买入评级
证券之星 · 06-09
山西证券：给予百利天恒买入评级
百利天恒(688506.SH)：BL-M14D1(DLL3ADC)联合免疫治疗用于一线广泛期小细胞肺癌患者的III期临床试验申请获得FDA许可
智通财经网 · 06-08
百利天恒(688506.SH)：BL-M14D1(DLL3ADC)联合免疫治疗用于一线广泛期小细胞肺癌患者的III期临床试验申请获得FDA许可
每周股票复盘：百利天恒（688506）拟回购1亿至2亿元股份
证券之星 · 06-07
每周股票复盘：百利天恒（688506）拟回购1亿至2亿元股份
依托成熟毒素平台 百利天恒BL-M05D1胃癌III期试验完成首例入组
财中社 · 06-04
依托成熟毒素平台 百利天恒BL-M05D1胃癌III期试验完成首例入组
百利天恒：注射用BL-M08D1获临床试验批准
南方财经网 · 06-04
百利天恒：注射用BL-M08D1获临床试验批准
公募FOF年内新发规模超千亿元；谢治宇、葛兰调仓百利天恒
每日经济新闻 · 06-04
公募FOF年内新发规模超千亿元；谢治宇、葛兰调仓百利天恒
百利天恒（688506）披露以集中竞价交易方式首次回购公司股份的公告，6月3日股价下跌0.08%
证券之星 · 06-03
百利天恒（688506）披露以集中竞价交易方式首次回购公司股份的公告，6月3日股价下跌0.08%
百利天恒(688506.SH)拟1亿元至2亿元回购股份
智通财经 · 06-01
百利天恒(688506.SH)拟1亿元至2亿元回购股份
百利天恒跌10.66% 华泰证券喊买入后股价屡跌
中金财经 · 06-01
百利天恒跌10.66% 华泰证券喊买入后股价屡跌
5月29日百利天恒涨8.64%，中欧医疗健康混合A基金重仓该股
证券之星 · 05-29
5月29日百利天恒涨8.64%，中欧医疗健康混合A基金重仓该股
百利天恒涨8.64%，开源证券一个月前给出“买入”评级
证券之星 · 05-29
百利天恒涨8.64%，开源证券一个月前给出“买入”评级
百利天恒跌6.83% 招商证券在历史大顶发研报强烈推荐
中金财经 · 05-28
百利天恒跌6.83% 招商证券在历史大顶发研报强烈推荐
东吴证券：给予百利天恒买入评级
证券之星 · 05-25
东吴证券：给予百利天恒买入评级
每周股票复盘：百利天恒（688506）2025年净亏损10.54亿元，营收降56.72%
证券之星 · 05-24
每周股票复盘：百利天恒（688506）2025年净亏损10.54亿元，营收降56.72%
暂无数据
公司概况
公司名称：
四川百利天恒药业股份有限公司
所属行业：
医药制造业
上市日期：
2023-01-06
主营业务：
四川百利天恒药业股份有限公司的主营业务是创新生物药业务和化药制剂、中成药制剂业务。公司的主要产品是知识产权收入、化药制剂、中成药制剂。
发行价格：
24.70
{"stockData":{"symbol":"688506","market":"SH","secType":"STK","nameCN":"百利天恒","latestPrice":229.43,"timestamp":1781766001000,"preClose":230,"halted":0,"volume":2421700,"delay":0,"changeRate":-0.0025,"floatShares":413000000,"shares":413000000,"eps":-3.1408,"marketStatus":"已收盘","change":-0.57,"latestTime":"06-18 15:00:01","open":227.67,"high":243.26,"low":225.2,"amount":564000000,"amplitude":0.0785,"askPrice":230.61,"askSize":28,"bidPrice":229.43,"bidSize":20,"shortable":0,"etf":0,"ttmEps":-3.1408,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1782091800000},"marketStatusCode":5,"adr":0,"adjPreClose":230,"symbolType":"stock_kcb","openAndCloseTimeList":[[1781746200000,1781753400000],[1781758800000,1781766000000]],"highLimit":253,"lowLimit":207,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":412873817,"isCdr":false,"pbRate":16.78,"roa":"--","roe":"--","epsLYR":-2.61,"committee":0.462963,"marketValue":94726000000,"turnoverRate":0.0059,"status":1,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2026-06-22。","afterMarket":{"amount":0,"volume":0,"close":229.43,"buyVolume":390,"sellVolume":0,"time":1781768037746,"indexStatus":"已收盘 06-18 15:30:00","preClose":230},"hkstockBrief":{"symbol":"02615","market":"HK","secType":"STK","nameCN":"百利天恒","latestPrice":0,"timestamp":1781769600000,"preClose":0,"halted":7,"volume":0,"delay":0,"premium":"-100.00"},"floatMarketCap":94726000000},"requestUrl":"/m/hq/s/688506/tweets","defaultTab":"tweets","newsList":[{"id":"2643466202","title":"百利天恒最新公告：EGFR×HER3双抗ADC治疗三阴乳腺癌上市申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2643466202","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643466202?lang=zh_cn&edition=full","pubTime":"2026-06-14 16:20","pubTimestamp":1781425238,"startTime":"0","endTime":"0","summary":"百利天恒(688506.SH)公告称，公司自主研发的全球首创EGFR×HER3双抗ADC(iza-bren)用于治疗局部晚期或转移性三阴乳腺癌的药品上市申请已获国家药监局药审中心受理。该申请基于III期临床试验期中分析结果，该试验达到无进展生存期和总生存期双主要终点，为全球首个双抗ADC在三阴乳腺癌中取得双阳性结果的III期研究。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061400003053.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["02615","688506","91194","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643582246","title":"百利天恒最新公告：注射用BL-M14D1（DLL3ADC）联合用药治疗广泛期小细胞肺癌药物临床试验获批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2643582246","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643582246?lang=zh_cn&edition=full","pubTime":"2026-06-14 16:00","pubTimestamp":1781424002,"startTime":"0","endTime":"0","summary":"百利天恒(688506.SH)公告称，公司近日收到国家药品监督管理局(NMPA)正式批准签发的《药物临床试验批准通知书》，公司自主研发的创新生物药BL-M14D1（DLL3 ADC）的联合用药的临床试验获得批准，同意该药品开展联合PD-1/PD-L1单抗±抗血管生成药物±化疗治疗广泛期小细胞肺癌的临床试验。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061400002006.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688506","91194","BK0239","02615"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642110265","title":"百利天恒涨6.24%，开源证券一个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2642110265","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642110265?lang=zh_cn&edition=full","pubTime":"2026-06-12 16:30","pubTimestamp":1781253002,"startTime":"0","endTime":"0","summary":"今日百利天恒涨6.24%，收盘报232.0元。2026年4月29日，开源证券研究员余汝意,聂媛媛发布了对百利天恒的研报《Iza-bren商业化在即，多产品将开展全球注册临床》，该研报对百利天恒给出“买入”评级。研报中预计公司2026-2028年营收为24.76/22.99/30.76，当前股价对应PE分别为47.5/51.5/38.2倍，维持“买入”评级。此外，山西证券研究员邓周宇,魏赟,张智勇，东吴证券研究员朱国广近期也对该股发布了研报，同样给出“买入”评级。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061200025400.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["02615","161027","688506","91194"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642820662","title":"百利天恒：60亿元科技创新债券注册获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2642820662","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642820662?lang=zh_cn&edition=full","pubTime":"2026-06-11 20:58","pubTimestamp":1781182680,"startTime":"0","endTime":"0","summary":"6月11日，百利天恒（688506）发布公告，公司收到中国银行间市场交易商协会出具的《接受注册通知书》，决定接受公司科技创新债券注册。本次注册的基础品种为中期票据，注册金额为60亿元，注册额度自《接受注册通知书》落款之日起2年内有效，在注册有效期内，公司可分期发行科技创新债券，并将根据市场情况适时安排中期票据的发行。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606113768540761.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0239","688506","02615","BNDW","91194"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188393609","title":"百利天恒获准发行60亿元中期票据","url":"https://stock-news.laohu8.com/highlight/detail?id=1188393609","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1188393609?lang=zh_cn&edition=full","pubTime":"2026-06-11 19:04","pubTimestamp":1781175879,"startTime":"0","endTime":"0","summary":"百利天恒已获得银行间市场交易商协会的批准，将发行总额为60亿元人民币的中期票据。此次发行标志着公司在资本运作方面取得了新的进展，有助于优化其债务结构并拓宽融资渠道。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688506","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642449086","title":"6月10日百利天恒涨5.30%，中欧医疗健康混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2642449086","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642449086?lang=zh_cn&edition=full","pubTime":"2026-06-10 16:40","pubTimestamp":1781080815,"startTime":"0","endTime":"0","summary":"证券之星消息，6月10日百利天恒涨5.30%，收盘报219.98元，换手率0.67%，成交量2.78万手，成交额6.03亿元。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共128家，其中持有数量最多的公募基金为中欧基金的中欧医疗健康混合A。中欧医疗健康混合A目前规模为129.74亿元，最新净值1.5035，较上一交易日上涨0.53%，近一年下跌14.06%。中欧医疗健康混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061000029349.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159760","91194","02615","BK0239","688506"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642246107","title":"山西证券：给予百利天恒买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2642246107","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642246107?lang=zh_cn&edition=full","pubTime":"2026-06-09 18:43","pubTimestamp":1781001805,"startTime":"0","endTime":"0","summary":"山西证券股份有限公司邓周宇,魏赟,张智勇近期对百利天恒进行研究并发布了研究报告《EGFR×HER3双抗ADC iza-bren硕果频出，多管线驱动成长》，给予百利天恒买入评级。iza-bren后线鼻咽癌、后线食管鳞癌NDA受理并纳入优先审评；三阴性乳腺癌III期达主要终点，计划提交NDA。持续覆盖，给予“买入-B”评级。最新盈利预测明细如下：该股最近90天内共有4家机构给出评级，买入评级4家；过去90天内机构目标均价为361.02。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060900030326.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002500","91194","02615","688506"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641045171","title":"百利天恒(688506.SH)：BL-M14D1(DLL3ADC)联合免疫治疗用于一线广泛期小细胞肺癌患者的III期临床试验申请获得FDA许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2641045171","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641045171?lang=zh_cn&edition=full","pubTime":"2026-06-08 15:36","pubTimestamp":1780904174,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百利天恒 发布公告，公司的全资子公司 SystImmune,Inc.近日收到美国食品药品监督管理局的通知， BL-M14D1联合免疫治疗用于一线广泛期小细胞肺癌患者的III期临床试验申请已获得FDA许可。BL-M14D1与iza-bren 共享同一小分子技术平台，公司拥有其完整的全球权益。本次BL-M14D1的III期临床研究获得FDA的IND许可，将进一步推进公司业务和产品国际化布局的进程，对公司近期业绩不会产生重大影响。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1451325.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BL","02615","91194","BK4023","BK4588","LU0757428866.USD","LU1815336091.USD","III","688506","BK4585","BK4134","LABU","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641812784","title":"每周股票复盘：百利天恒（688506）拟回购1亿至2亿元股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2641812784","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641812784?lang=zh_cn&edition=full","pubTime":"2026-06-07 01:55","pubTimestamp":1780768512,"startTime":"0","endTime":"0","summary":"截至2026年6月5日收盘，百利天恒报收于212.29元，较上周的238.57元下跌11.02%。本周，百利天恒6月1日盘中最高价报243.9元。本周关注点公司公告汇总：百利天恒拟以集中竞价交易方式回购股份，金额不低于10,000万元且不超过20,000万元。公司公告汇总四川百利天恒药业股份有限公司于2026年6月1日召开第五届董事会第八次会议，审议通过《关于以集中竞价交易方式回购公司股份方案的议案》。董事会已授权公司管理层办理本次回购相关事宜。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060700000479.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688506","02615","BK0239","91194"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640197152","title":"依托成熟毒素平台 百利天恒BL-M05D1胃癌III期试验完成首例入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2640197152","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640197152?lang=zh_cn&edition=full","pubTime":"2026-06-04 19:52","pubTimestamp":1780573920,"startTime":"0","endTime":"0","summary":"6月4日，百利天恒（688506）发布公告，公司自主研发的创新生物药注射用BL-M05D1（Claudin18.2ADC）用于在既往经一线治疗的Claudin18.2阳性晚期胃癌或胃食管结合部腺癌的III期临床试验已完成首例受试者入组。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606043760581427.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BL","02615","91194","BK4023","LU0757428866.USD","LU1815336091.USD","III","688506","BK4134","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640154692","title":"百利天恒：注射用BL-M08D1获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2640154692","media":"南方财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640154692?lang=zh_cn&edition=full","pubTime":"2026-06-04 18:54","pubTimestamp":1780570440,"startTime":"0","endTime":"0","summary":"南财智讯6月4日电，百利天恒公告，百利天恒（简称）收到国家药品监督管理局正式批准签发的《药物临床试验批准通知书》。公司自主研发的创新生物药注射用BL-M08D1（ADC）联合用药的临床试验获得批准，适应症为弥漫大B细胞淋巴瘤。该药物与iza-bren出自同一技术平台，共享同一“连接子+毒素”平台。公司将按规定积极推进研发项目，并及时履行后续信息披露义务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606043760550358.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["91194","LU0757428866.USD","688506","BL","BK4023","BK0239","02615","LU1815336091.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640115566","title":"公募FOF年内新发规模超千亿元；谢治宇、葛兰调仓百利天恒","url":"https://stock-news.laohu8.com/highlight/detail?id=2640115566","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640115566?lang=zh_cn&edition=full","pubTime":"2026-06-04 17:02","pubTimestamp":1780563760,"startTime":"0","endTime":"0","summary":"天赐良基日报第889期一、今日基金新闻速览1、公募FOF年内新发规模超千亿元公开数据显示，按认购起始日计算，截至6月3日，今年以来新发FOF产品91只，其中80只产品（份额合并计算）已经结募并公布认购情况，有效认购金额合计达到1049.07亿元。2、科技主题基金业绩现分化Wind数据显示，截至6月1日，名字中带“科技”的主动权益类基金中，今年以来回报率最高的基金业绩接近80%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202606043760472889.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606043760472889.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["FOF","91194","02615","BK0239","688506"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640908454","title":"百利天恒（688506）披露以集中竞价交易方式首次回购公司股份的公告，6月3日股价下跌0.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2640908454","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640908454?lang=zh_cn&edition=full","pubTime":"2026-06-03 17:43","pubTimestamp":1780479806,"startTime":"0","endTime":"0","summary":"截至2026年6月3日收盘，百利天恒报收于212.13元，较前一交易日下跌0.08%，最新总市值为875.83亿元。该股当日开盘211.98元，最高214.98元，最低207.5元，成交额达3.48亿元，换手率为0.4%。近日，四川百利天恒药业股份有限公司发布《关于以集中竞价交易方式首次回购公司股份的公告》。本次回购股份用于员工持股计划或股权激励，回购期限为2026年6月1日至2027年5月31日，拟回购金额为10,000万元至20,000万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060300036130.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688506","BK0239","02615","91194"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640593669","title":"百利天恒(688506.SH)拟1亿元至2亿元回购股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2640593669","media":"智通财经","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640593669?lang=zh_cn&edition=full","pubTime":"2026-06-01 19:42","pubTimestamp":1780314167,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百利天恒(688506.SH)发布公告，公司拟1亿元至2亿元回购股份，回购价格不超过398元/股，回购的股份将在未来适宜时机全部用于实施员工持股计划或股权激励。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1448691.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688506","02615","91194","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640375239","title":"百利天恒跌10.66% 华泰证券喊买入后股价屡跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2640375239","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640375239?lang=zh_cn&edition=full","pubTime":"2026-06-01 17:01","pubTimestamp":1780304468,"startTime":"0","endTime":"0","summary":"中国经济网北京6月1日讯 百利天恒(688506.SH)今日收报213.15元，跌幅10.66%。百利天恒5月25日以来6个交易日中有4个交易日股价下跌。\r\n\r\n 华泰证券股份有限公司研究员代雯、袁中平5月25日发布研报《百利天恒(688506)：ASCO大会多项数据将密集披露》称，维持“买入”。\r\n\r\n (责任编辑：徐自立)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20260601/32266270.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0239","LU0164865239.USD","LU1064130708.USD","688506","LU1934453819.USD","LU1979443071.USD","601688","LU0039217434.USD","LU1781817850.SGD","LU1580142542.USD","BK0028","BK0183","LU1064131003.USD","BK0276","LU2148510915.USD","LU1328615791.USD","BK0188","91194","LU1808992512.USD","LU0531971595.HKD","02615","BK0012","LU0871576103.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639965628","title":"5月29日百利天恒涨8.64%，中欧医疗健康混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2639965628","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639965628?lang=zh_cn&edition=full","pubTime":"2026-05-29 16:41","pubTimestamp":1780044062,"startTime":"0","endTime":"0","summary":"证券之星消息，5月29日百利天恒涨8.64%创60日新低，收盘报238.57元，换手率1.21%，成交量5.0万手，成交额11.68亿元。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共128家，其中持有数量最多的公募基金为中欧基金的中欧医疗健康混合A。中欧医疗健康混合A目前规模为129.74亿元，最新净值1.5925，较上一交易日下跌2.4%，近一年下跌1.79%。中欧医疗健康混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052900030299.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","159760","91194","688506","02615"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639628197","title":"百利天恒涨8.64%，开源证券一个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2639628197","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639628197?lang=zh_cn&edition=full","pubTime":"2026-05-29 16:40","pubTimestamp":1780044053,"startTime":"0","endTime":"0","summary":"今日百利天恒涨8.64%，收盘报238.57元。2026年4月29日，开源证券研究员余汝意,聂媛媛发布了对百利天恒的研报《Iza-bren商业化在即，多产品将开展全球注册临床》，该研报对百利天恒给出“买入”评级。研报中预计公司2026-2028年营收为24.76/22.99/30.76，当前股价对应PE分别为47.5/51.5/38.2倍，维持“买入”评级。百利天恒个股概况：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052900030286.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","02615","91194","688506"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638613056","title":"百利天恒跌6.83% 招商证券在历史大顶发研报强烈推荐","url":"https://stock-news.laohu8.com/highlight/detail?id=2638613056","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638613056?lang=zh_cn&edition=full","pubTime":"2026-05-28 17:34","pubTimestamp":1779960844,"startTime":"0","endTime":"0","summary":"中国经济网北京5月28日讯 百利天恒(688506.SH)今日收报219.60元，跌幅6.83%。\r\n\r\n 2025年9月8日，百利天恒股价盘中创上市以来高点414.02元。\r\n\r\n 招商证券股份有限公司研究员梁广楷、许菲菲、焦玉鹏2025年9月12日发布研报《百利天恒(688506)：从双抗ADC出发 多平台布局迈向国际领先的MNC》称，给予“强烈推荐”投资评级。\r\n\r\n 国泰海通证券股份有限公司研究员余文心、廖博闻2025年9月12日发布研报《百利天恒(688506)：WCLC上公布全球BIC数据 IZA-BREN有望冲击一线市场》称，维持增持评级。\r\n\r\n (责任编辑：徐自立)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20260528/32261611.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0239","91194","688506","BK0188","02615","BK0010","BK0028","06099","BK1564","600999","BK0276","BK0012","BK0183","BK1147"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638537856","title":"东吴证券：给予百利天恒买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2638537856","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638537856?lang=zh_cn&edition=full","pubTime":"2026-05-25 19:01","pubTimestamp":1779706876,"startTime":"0","endTime":"0","summary":"东吴证券股份有限公司朱国广近期对百利天恒进行研究并发布了研究报告《iza-bren领衔亮相，5款新药7项数据登陆ASCO》，给予百利天恒买入评级。我们认为公司以iza-bren为首的平台技术领先，商业化潜力大，研发顺利推进，待公司后续创新产品兑现实现扭亏，维持“买入”评级。最新盈利预测明细如下：该股最近90天内共有3家机构给出评级，买入评级3家；过去90天内机构目标均价为361.02。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052500026911.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["601555","91194","688506","02615"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637137365","title":"每周股票复盘：百利天恒（688506）2025年净亏损10.54亿元，营收降56.72%","url":"https://stock-news.laohu8.com/highlight/detail?id=2637137365","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637137365?lang=zh_cn&edition=full","pubTime":"2026-05-24 02:20","pubTimestamp":1779560417,"startTime":"0","endTime":"0","summary":"截至2026年5月22日收盘，百利天恒报收于240.06元，较上周的257.01元下跌6.6%。本周，百利天恒5月21日盘中最高价报261.0元。来自业绩披露要点：2025年营业收入为252,011.33万元，同比下降56.72%。出席会议的股东及代理人共223人，代表有表决权股份总数的80.2594%。中信证券股份有限公司作为保荐人，对四川百利天恒药业股份有限公司2025年度持续督导期间的经营与财务状况进行跟踪。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052400000519.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["91194","02615","688506"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1782054546215,"stockEarnings":[{"period":"1week","weight":0.0506},{"period":"1month","weight":-0.0712},{"period":"3month","weight":-0.1549},{"period":"6month","weight":-0.353},{"period":"1year","weight":-0.2455},{"period":"ytd","weight":-0.2899}],"compareEarnings":[{"period":"1week","weight":0.026},{"period":"1month","weight":-0.019},{"period":"3month","weight":0.0337},{"period":"6month","weight":0.0514},{"period":"1year","weight":0.2071},{"period":"ytd","weight":0.0306}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"四川百利天恒药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"7777人(较上一季度增加34.99%)","perCapita":"53089股","listingDate":"2023-01-06","address":"四川省成都市温江区成都海峡两岸科技产业园百利路161号一幢一号","registeredCapital":"41287万元","survey":" 四川百利天恒药业股份有限公司的主营业务是创新生物药业务和化药制剂、中成药制剂业务。公司的主要产品是知识产权收入、化药制剂、中成药制剂。","listedPrice":24.7},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"百利天恒(688506)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供百利天恒(688506)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"百利天恒,688506,百利天恒股票,百利天恒股票老虎,百利天恒股票老虎国际,百利天恒行情,百利天恒股票行情,百利天恒股价,百利天恒股市,百利天恒股票价格,百利天恒股票交易,百利天恒股票购买,百利天恒股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"百利天恒(688506)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供百利天恒(688506)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}